XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Option Activity
A summary of the stock option activity under the Company’s equity plans and inducement awards for the nine months ended September 30, 2022 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Exercise
Price
Options outstanding at December 31, 20211.4 $20.36 
Less:
Options exercised— $26.22 
Options canceled or expired(0.6)$26.85 
Options outstanding at September 30, 20220.8 $15.62 
Options exercisable at September 30, 20220.5 $16.99 
Schedule of Restricted Stock Unit Activity
A summary of the RSU awards activity under the Company’s equity plans and inducement awards, including PSU awards, for the nine months ended September 30, 2022 is as follows:
(number of shares in millions)Number
of
Shares
Weighted
Average
Grant Date
Fair Value
RSUs outstanding at December 31, 20213.1 $24.96 
RSUs granted1.9 $26.09 
Less:
RSUs vested(1.0)$27.27 
RSUs canceled(0.3)$26.57 
RSUs outstanding at September 30, 20223.7 $24.75 
Schedule of Stock-Based Compensation Expense
Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) was allocated as follows:
Three months ended
September 30,
Nine months ended
September 30,
(in millions)2022202120222021
Cost of molecular diagnostic testing$0.5 $0.4 $1.3 $1.1 
Cost of pharmaceutical and clinical services— — — 0.1 
Research and development expense1.0 0.8 4.4 3.3 
Selling, general, and administrative expense7.9 8.8 24.2 23.4 
     Total stock-based compensation expense$9.4 $10.0 $29.9 $27.9